Comparative in vivo safety and efficacy of a glycoprotein G-deficient candidate vaccine strain of infectious laryngotracheitis virus delivered via eye drop

Infectious laryngotracheitis (ILT) is an acute respiratory disease in poultry that is commonly controlled by vaccination with conventionally attenuated virus strains. Despite the use of these vaccines, ILT remains a threat to the intensive poultry industry. Our laboratory has developed a novel candidate vaccine strain of infectious laryngotracheitis virus (ILTV) lacking glycoprotein G (ΔgG-ILTV). The aim of the present study was to directly compare this candidate vaccine with three currently available commercial vaccines in vivo. Five groups of specific-pathogen-free chickens were eye-drop inoculated with one of the three commercial vaccine strains (SA2-ILTV, A20-ILTV or Serva-ILTV), or ΔgG-ILTV, or sterile medium. Vaccine safety was assessed by examining clinical signs, weight gain and persistence of virus in the trachea. Vaccine efficacy was assessed by scoring clinical signs and conducting post-mortem analyses following challenge with virulent virus. Following vaccination, birds that received ΔgG-ILTV had the highest weight gain among the vaccinated groups and had clinical scores that were significantly lower than birds vaccinated with SA2-ILTV or A20-ILTV, but not significantly different from those of birds vaccinated with Serva-ILTV. Analysis of clinical scores, weight gain, tracheal pathology and virus replication after challenge revealed a comparable level of efficacy for all vaccines. Findings from this study further demonstrate the suitability of ΔgG-ILTV as a vaccine to control ILT.     

Efficacy of Marek's disease vaccines: protection and viraemia studies with turkey herpes virus vaccines

Two freeze dried turkey herpes virus vaccines A and C, of similar virus content were administered in graded doses to groups of day old chicks which were genetically susceptible to Marek's disease. Immediately after vaccination the chicks were challenged by contact with 4-weeks-old birds that had been infected at one day of age with virulent Marek's disease virus strain HPRS 16. Assessment of protection against Marek's disease was based on the absence of gross lesions after a 15 week observation period and a significant difference in the protective capacity of the 2 products was found. From the relationship between protection and vaccine dose that was obtained with vaccine C it was calculated that 0.48 of a field dose protected 50% of the birds. Vaccine A provided no significant protection at any dose level. Isolation of vaccinal virus 3 weeks after administration of graded doses of vaccines A and B revealed that a significantly higher dose of vaccine A was required to produce viraemia in vaccinated birds. Determination of viraemia at intervals following inoculation of one field dose of the vaccines demonstrated that Vaccine A also induced a less rapid response than the other 2 vaccines. These effects were not related to the virus content of the vaccines.     

Hatchability, serology and virus excretion following in ovo vaccination of chickens with an avian metapneumovirus vaccine.

The present investigation describes for the first time the effect of an avian metapneumovirus vaccine administered in ovo to 18-day-old chicken embryos. The application of the vaccine had no adverse effect on the hatchability or the health of the chicks post hatch. The antibody titres achieved were higher than those determined for birds vaccinated at 1 day old. Not only were the mean titres in the in ovo vaccinated groups higher, but many more birds developed a measurable antibody response than birds vaccinated at 1 day old. Variation of the vaccine dose used in ovo had little effect on the serological responses that peaked 21 to 28 days post hatch. Re-isolation of the vaccine virus was much more successful from birds vaccinated in ovo than from birds vaccinated at 1 day old, and detection of the nucleic acid by polymerase chain reaction correlated with the results of live virus isolation.     

Comparison of the replication and transmissibility of two infectious laryngotracheitis virus chicken embryo origin vaccines delivered via drinking water

Infectious laryngotracheitis (ILT) is an acute infectious viral disease that affects chickens, causing respiratory disease, loss of production and mortality in severe cases. Biosecurity measures and administration of attenuated viral vaccine strains are commonly used to prevent ILT. It is notable that most recent ILT outbreaks affecting the intensive poultry industry have been caused by vaccine-related virus strains. The purpose of this study was to characterize and compare viral replication and transmission patterns of two attenuated chicken embryo origin ILT vaccines delivered via the drinking water. Two groups of specific pathogen free chickens were each inoculated with SA-2 ILT or Serva ILT vaccine strains. Unvaccinated birds were then placed in contact with vaccinated birds at regular intervals. Tracheal swabs were collected every 4 days over a period of 60 days and examined for the presence and amount of virus using a quantitative polymerase chain reaction. A rapid increase in viral genome copy numbers was observed shortly after inoculation with SA-2 ILT virus. In contrast, a comparatively delayed virus replication was observed after vaccination with Serva ILT virus. Transmission to in-contact birds occurred soon after exposure to Serva ILT virus but only several days after exposure to SA-2 ILT virus. Results from this study demonstrate in vivo differences between ILT vaccine strains in virus replication and transmission patterns.     

Evaluation of the protection elicited by direct and indirect exposure to live attenuated infectious laryngotracheitis virus vaccines against a recent challenge strain from the United States

In a recent study (Oldoni & García, 2007), some field strains of infectious laryngotracheitis viruses (ILTV) were characterized as genotypically different (group VI) from ILT vaccine strains. The objective of this study was to evaluate the protection elicited by one chicken embryo origin (CEO) and one tissue culture origin (TCO) vaccine against a field isolate from group VI after direct and indirect exposure to ILTV live attenuated vaccines. In phase 1 of the experiment, non-vaccinated chickens were placed into contact with the eye drop vaccinates for a period of four weeks after vaccination. Transmission of the vaccine virus to these in-contact birds was demonstrated by real time PCR and antibody production, although the in-contact birds did not become protected against disease when subsequently challenged in phase 2 of the experiment. This emphasized the importance of uniform vaccination to obtain adequate protection, both to avoid the occurrence of susceptible chickens, and to minimize the potential for reversion to virulence of live-attenuated vaccines. In phase 2, protection against challenge with a group VI field virus was assessed four weeks after vaccination by scoring clinical signs and mortality, and quantifying weight gain. Sentinel birds were added to the groups one day after challenge to assess shedding of challenge virus, using real time PCR and virus isolation, during the period 2 to 12 days post challenge. The results showed that the CEO and TCO eye drop-vaccinated chickens were protected against challenge with the group VI virus, even though it was genetically different from the vaccine strains, and that challenge virus was not transmitted from these protected birds to the sentinels.     

Potency of an inactivated influenza vaccine prepared from A/duck/Hong Kong/960/1980 (H6N2) against a challenge with A/duck/Vietnam/OIE-0033/2012 (H6N2) in mice

H6 influenza viruses are prevalent in domestic and wild birds in Eurasian countries and have been isolated from pigs and a human. To prepare for an influenza pandemic, we have established an influenza virus library consisting of more than 1,300 influenza virus strains, including 144 combinations of 16 hemagglutinin and 9 neuraminidase subtypes. H6 viruses in the library were classified into Early, Group II, Group III, and W312 sublineages and the North America lineage on the basis of their phylogenetic features. Chicken antisera to A/duck/Hong Kong/960/1980 (H6N2) of the Early sublineage broadly reacted with viruses of different sublineages in a hemagglutinin inhibition test. A whole inactivated virus particle vaccine was prepared from A/duck/Hong Kong/960/1980 (H6N2) which was stocked in the influenza virus library. The potency of this vaccine against A/duck/Vietnam/OIE-0033/2012 (H6N2), which belongs to a different sublineage, was evaluated in mice. The test vaccine was sufficiently potent to induce an immune response that reduced the impact of disease caused by a challenge with A/duck/Vietnam/OIE-0033/2012 (H6N2) in mice. The present results indicate that the whole inactivated virus particle vaccine prepared from a virus strain in the influenza virus library is useful as a vaccine against pandemic influenza.     

Correlation of Marek's disease herpesvirus vaccine virus genome load in feather tips with protection, using an experimental challenge model.

We previously developed a real-time polymerase chain reaction (PCR) assay for absolute quantitation of serotype 1 Marek's disease virus in feather tips of chickens, and this has been used clinically to monitor a flock's response following vaccination with CVI988, an attenuated serotype 1 strain. The level of vaccine virus in feather tips associated with protection against challenge by virulent virus is not known. Here, we used an experimental challenge model, in which one dose of vaccine gives over 90% protection against mortality, to investigate correlation between the CVI988 level in feathers and protection. One-day-old chickens were vaccinated with 1, 0.1 or 0.01 commercial dose of CVI988 vaccine, and were then challenged with a virulent strain (RB-1B) 14, 21 or 28 days later. Replication of CVI988 virus was followed in each bird by real-time PCR analysis of feather DNA samples. Since the PCR does not differentiate between CVI988 and RB-1B, samples were taken only prior to challenge to ensure that the virus being measured was CVI988. Administration of one dose of vaccine ensured a uniform, rapid and high replication amongst birds, while replication following administration of the 0.1 or 0.01 dose was very variable. However, given time, a low early level of vaccine virus eventually replicated to high levels in some birds. Both the dose of vaccine virus administered and the level of vaccine virus in feather tips at 13 days post vaccination showed significant correlation with protection against challenge. A level of CVI988 vaccine virus of 132 genome copies/10000 feather tip cells was calculated to be the level required for 90% protection in this experimental model. The potential of this assay, and its limitations for monitoring protection in the field, are discussed.     

A monoclonal antibody-based competitive enzyme-linked immunosorbent assay for detecting antibody production against avian reovirus protein sigmaA

An assay protocol based on a monoclonal antibody-based competitive enzyme-linked immunosorbent assay (MAb-based c-ELISA) for detection of antibody against avian reovirus protein sigmaA in chicken is described. After the conditions for MAb-based c-ELISA had been optimized, sera collected from birds that received live and inactivated avian reovirus vaccines in different combinations were tested for antibody response against virus protein sigmaA. The results show a high level of antibody against sigmaA was in both vaccinated specific pathogenic free (SPF) and vaccinated commercially reared birds as long as one of the vaccines administered was in an inactivated form. The high level of antibody production is indicated by a high percentage inhibition (PI) values in the sera of the birds; but no antibody production was found in birds which received live vaccine only, as indicated by the low PI values. In serum samples from SPF birds receiving vaccines that include an inactivated form of the vaccine, there is a good correlation between the PI values and serum neutralizing antibody (SN) titers. Again, this correlation was not observed in birds that received only live vaccine. The PI values of commercially reared birds receiving inactivated vaccine were significantly different from those of the mock-treated birds, but this was not the case when the birds received only live vaccine. Taken together, the results suggest that MAb-based c-ELISA may provide an alternative choice for determining the immune status of a vaccinated chicken flock as long as one of the vaccines used was inactivated, and thus would allow a more precise way to predict the appropriate time for vaccination.     

Primary Newcastle disease vaccination of broilers: comparison of the antibody seroresponse and adverse vaccinal reaction after eye–nose drop or coarse spray application,and implication of the results for a previously developed coarse dry powder vaccine

To compare antibody seroresponse and adverse vaccinal reaction induced by Newcastle disease (ND) vaccination after eye–nose drop or coarse spray, groups of SPF broiler hens were vaccinated at day 4 (day of hatch is day 0) and intratracheally inoculated with Escherichia coli at day 11. Body weight gain (BWG) was assessed between day 4 and day 18; colibacillosis lesions and serum antibodies were determined at day 18. Meaningful comparison requires similar vaccine uptake. Vaccine virus loss during spray relative to eye–nose drop, which was assessed by comparing the results of endpoint titrations, was 3 log₁₀. Colibacillosis lesions in birds spray vaccinated with 10^6.4 EID₅₀/chicken were significantly more severe (P?3.4 EID₅₀/chicken, while the seroresponse was slightly but significantly (P?相似文献   

Duration of immunity produced by a live attenuated vaccine against avian pneumovirus type C.

A recently developed live, attenuated vaccine against avian pneumovirus (APV) was found to be safe and protective in experimental birds. Duration of immunity following a single dose of this experimental vaccine in 1-week-old turkey poults is described. Two groups each of 60 poults were housed in separate isolation rooms. Birds in group one were inoculated oculonasally at 1 week of age with the vaccine. The second group served as a non-vaccinated group and was inoculated with mock-infected cell culture fluid. At 3, 7, 10, and 14 weeks post vaccination, 15 birds from each of the groups were removed to separate isolation rooms and challenged with virulent APV. Taken together, data on clinical signs and virus detection in choanal swabs following each challenge indicated that the vaccine was able to protect birds for up to 14 weeks post vaccination. Peak antibody levels were attained 7 weeks post vaccination and declined thereafter. These results indicated that this experimental vaccine induced protection against APV even in the absence of high antibody titres.     

Efficacy of inactivated vaccines against H5N1 avian influenza infection in ducks

The current Asian H5N1 highly pathogenic avian influenza virus has spread over much of Asia and into Europe and Africa. As well as affecting village and commercial chicken operations in many South East Asian countries, it differs from past H5 avian influenza viruses in that it causes morbidity and mortalities in other domesticated birds, such as ducks and turkeys and in wild water birds. Effective vaccines that can prevent infection, as well as disease, and be used in a variety of avian species are needed for field use. In this report, a bivalent H5N9+H7N1 oil emulsion vaccine is compared, in ducks, to a monovalent H5N3 oil emulsion vaccine that has been derived by reverse genetics with an H5 from A/chicken/Vietnam/C58/04. While both vaccines protected against morbidity, the monovalent vaccine provided effective protection, with no evidence of shedding of the challenge virus and no serological response to the H5N1 challenge virus.     

Protection following simultaneous vaccination with three or four different attenuated live vaccine types against infectious bronchitis virus

ABSTRACT

Two or more different live attenuated infectious bronchitis virus (IBV) vaccine types are often given to broilers to induce homologous protection as well as to broaden protection against other IBV types in the field. However, the ability of broilers to respond to three or four different antigenic types of IBV vaccine has not been examined experimentally. In this study, we vaccinated one-day-old broiler chicks by eyedrop with three or four different IBV vaccine types simultaneously. The presence and relative amount of each vaccine was examined in all of the birds by IBV type-specific real-time RT–PCR at 5 days post-vaccination and each vaccine was detected in all of the birds given that vaccine. The birds were challenged at 28 days of age and protection was measured by clinical signs, virus detection and by ciliostasis. Birds vaccinated with three different IBV types (Ark, Mass and GA98) were protected against challenge with each of those IBV types and were partially protected against challenge with the GA08 virus. Birds vaccinated with four different IBV types (Ark, Mass, GA98 and GA08) were protected against challenge with each of those IBV types with the exception of Mass challenged birds which clearly had 3/11 birds not protected based on individual ciliostasis scores, but had an average ciliostasis score of >50% which is considered protected. The results are important for the control of IBV because they indicate that simultaneous vaccination with up to four different IBV vaccine types can provide adequate protection against challenge for each type.     

Potency of an inactivated avian influenza vaccine prepared from a non-pathogenic H5N1 reassortant virus generated between isolates from migratory ducks in Asia

A reassortant influenza virus, A/duck/Hokkaido/Vac-1/2004 (H5N1) (Dk/Vac-1/04), was generated between non-pathogenic avian influenza viruses isolated from migratory ducks in Asia. Dk/Vac-1/04 (H5N1) virus particles propagated in embryonated chicken eggs were inactivated with formalin and adjuvanted with mineral oil to form a water-in-oil emulsion. The resulting vaccine was injected intramuscularly into chickens. The chickens were challenged with either of the highly pathogenic avian influenza virus strains A/chicken/Yamaguchi/7/2004 (H5N1) or A/swan/Mongolia/3/2005 (H5N1) at 21 days post-vaccination (p. v.), when the geometric mean serum HI titers of the birds was 64 with the challenge virus strains. The vaccinated chickens were protected from manifestation of disease signs upon challenge with either of the highly pathogenic avian influenza viruses. However, challenge virus was recovered at low titers from the birds at 2 and 4 days post-challenge (p.c.). All 3 chickens challenged at 6 days p.v. died, whereas 3 chickens challenged at 8 days p.v. survived. These results indicate that the present vaccine confers clinical protection and reduction of virus shedding against highly pathogenic avian influenza virus challenge and should be useful as an optional tool in emergency cases.     

A reovirus challenge model applicable in commercial broilers after live vaccination

The efficacy of live reovirus vaccines may be determined by challenge via the foot pad route 3 to 4 weeks after vaccination. Swelling and discoloration in the foot pad and shank are scored for a period of 14 days. The major disadvantages of this challenge model are the subjective judgement of gross foot pad and/or shank lesions, that it is very difficult to induce lesions in broilers, and that it causes animal suffering. Other reovirus challenge models are based on reisolation of the virus from different tissues or on scoring microscopic lesions in the tendons. Some disadvantages of these models are that they either cannot be used after vaccination with live reovirus because they cannot discriminate between vaccine and challenge virus or that the microscopic lesions scored need not necessarily be related to the challenge virus but may have been induced by other factors. Therefore, we have attempted to develop a reovirus challenge model that was an improvement on the existing ones, using isolation of reovirus from different organs followed by specific detection of the challenge virus with a monoclonal antibody that can discriminate between challenge and vaccine virus. The reovirus challenge model was examined in specific pathogen free (SPF) White Leghorn chickens and commercial broilers. In vivo studies were conducted to examine the efficacy of an attenuated reovirus vaccine in SPF White Leghorn chickens and commercial broilers with maternal immunity against reovirus. No challenge virus could be detected in any of the organs of the vaccinated chickens 3 and 10 days after challenge. In contrast, challenge virus could be isolated from the unvaccinated control group. At an increased challenge dose all unvaccinated challenge control birds were positive, while the vaccinated chickens were protected. It was shown that 1-day-old vaccination in the presence of maternal immunity was effective. It seemed that protection induced in broilers by the attenuated reovirus vaccine may not have been entirely humoral because in protected birds no antibodies against reovirus were detected by enzyme-linked immunosorbent at the time of challenge. Protection in these birds might therefore have been induced by cellular immunity.     

Recombinant egg drop syndrome subunit vaccine offers an alternative to virus propagation in duck eggs

Egg drop syndrome (EDS) virus vaccines are routinely produced in embryonated duck eggs (Solyom et al., 1982). This procedure poses the risk of dissemination of pathogens, such as avian influenza virus, as the eggs used are not from specific pathogen free birds. To address this problem, the knob and part of the shaft domain of the fibre protein of the EDS virus (termed knob-s) were expressed in Escherichia coli and assessed as a subunit vaccine. A single vaccination with the recombinant protein induced the production of anti-EDS virus antibodies, as detected by haemagglutination inhibition, enzyme-linked immunosorbent assay and virus neutralization tests, for at least 20 weeks. A positive correlation was demonstrated between these three assays. A dose-response assessment showed that the vaccine was effective over the range of 2 to 64 microg protein per dose. Two vaccinations with the recombinant protein, administered before the onset of lay, induced high haemagglutination inhibition antibody titres, comparable with those induced by an inactivated whole-virus vaccine. The vaccine did not have any adverse effects on egg production, quality or weight. The present study has shown that two vaccinations with the recombinant knob-s protein elicited high neutralizing antibody titres that persisted for more than 50 weeks of lay.     

The results of field trials conducted with an inactivated vaccine against the egg drop syndrome 76 (EDS 76)

The results of six vaccination trials carried out with a formalin inactivated oil adjuvant Egg Drop Syndrome 76 (EDS 76) vaccine prepared from strain BC14 are presented. The trials carried out in breeding and laying flocks of fowls always included vaccinated and unvaccinated birds. The birds were vaccinated once during the rearing period by intramuscular injection. Field infection with EDS 76 virus was confirmed by the sero-logical conversion to EDS antibody positive in the unvaccinated birds. In the unvaccinated birds field challenge was followed by typical EDS 76 symptoms, whereas the vaccinated birds were protected and layed normally throughout the trials.     

Infectious bronchitis in laying hens: interference with response to emulsion vaccine by attenuated live vaccine

Pullet chicks were reared in isolation; all except a control group were variously vaccinated against infectious bronchitis. Individual haemagglutination inhibition (HI) antibody responses were measured from 1 day to 38 weeks old when all birds were challenged with virulent infectious bronchitis virus, and egg production recorded for a further 5 week period. In the controls HI titres remained low until challenge: this caused a loss of 15.1 eggs/hen. In birds injected with oil emulsion killed vaccine (OEV) at 3 and 16 weeks old, the serological response was uniformly high but on challenge the loss in egg production was 2.9 eggs/bird. Birds given H120 live vaccine at 3 weeks and H52 live vaccine at 15 weeks old had a low (23%) individual rate of serological response to the latter, and egg production after challenge was 3.63 eggs/hen less than before. In birds given H120 live vaccine at 3 weeks and emulsion killed vaccine at 16 weeks old, 100% serological response to the latter occurred and egg production was unaffected by challenge. A further group also received H120 and H52 live vaccines at 3 and 15 weeks old respectively: however, they were then subdivided into four groups and injected with emulsion vaccine at either 17, 19, 21 or 23 weeks old. Their response to H52 vaccine was variable. The proportion of birds in each sub-group responding serologically to subsequent vaccination with OEV was 45, 65, 73 and 92% respectively. After challenge egg production in these four sub-groups was reduced by 1.92, 1.15, 0.94 and 1.55 eggs/bird respectively. It is concluded that response to oil emulsion infectious bronchitis vaccine can be impaired if it is used within 8 weeks of H52 live vaccine. Best results are achieved where birds are given a primary dose of H120 live vaccine at 3 weeks old followed by emulsion vaccine 12-16 weeks later. Use of the less attenuated H52 strain of live vaccine before emulsion killed vaccine is contra-indicated.     

Effect of phylogenetic diversity of velogenic Newcastle disease virus challenge on virus shedding post homologous and heterologous DNA vaccination in chickens

Newcastle disease (ND) is a highly devastating disease for the poultry industry as it causes high economic losses. In this present study, a DNA vaccine containing the F and HN surface antigens of a highly virulent Newcastle disease virus (NDV), NDV/1/Chicken/2005 (FJ939313), was successfully generated. Cell transfection test indicated that the vaccine expressed the F and HN genes in Hep-2 cells. The main objective of this study was to compare the extent of protection induced by DNA vaccination after homologous and heterologous NDV-challenge as determined by the amount of NDV shedding after challenge. NDV-antibody-negative chickens were vaccinated either once, twice or thrice intramuscularly at 7, 14 and 21 days old and were challenged 14 days post vaccination with either homologous virus (vaccine-matched velogenic viscerotropic Newcastle disease virus (vvNDV) strain, FJ939313), phylogenetically related to group VII, or a phylogenetically divergent heterologous virus (unmatched vvNDV strain, AY968809), which belongs to genogroup VI and shows 84.1% nucleotide similarity to the NDV-sequences of the DNA vaccine. Our data indicate that birds, which received a single dose of the DNA vaccine were poorly protected, and only 30–40% of these birds survived after challenge with high virus shedding titre. Multiple administration of the DNA vaccine induced high protection rates of 70–90% with reduced virus shedding compared to the non-vaccinated and challenged birds. Generally, homologous challenge led to reduced tracheal and cloacal shedding compared to the heterologous vvNDV strain. This study provides a promising approach for the control of ND in chickens using DNA vaccines, which are phylogenetically closely related to the circulating field strains.     

Histopathological and immunohistochemical study of air sac lesions induced by two strains of infectious bronchitis virus

Infectious bronchitis virus (IBV) is a highly contagious respiratory coronavirus of domestic chickens. Although mortality is low, infection with IBV results in substantial losses for the egg and meat chicken industries. Despite the economic importance of IBV and decades of research into the pathogenesis of infection, significant gaps in our knowledge exist. The aim of this study was to compare the early progression of air sac lesions in birds receiving a vaccine strain of the virus or a more virulent field strain. The air sacs are lined by different types of epithelia and are relatively isolated from the environment, so they represent a unique tissue in which to study virus-induced lesions. Both the pathogenic and vaccine strains of the virus produced significant lesions; however, the lesions progressed more rapidly in the birds receiving the pathogenic strain. Immunohistochemistry demonstrated that in birds infected with the pathogenic strain of virus, IBV spike protein is detected first in the ciliated cells lining the air sac. These preliminary data provide important clues regarding potential mechanisms for IBV tissue tropism and spread and show that the nature of the virus isolate influences the early progression of IBV infection.